

# Strongyloides stercoralis infection and long-term follow-up in a privately-owned dog from north-west of Italy

Federica Cagnasso, Luisa Rambozzi, Barbara Miniscalco, Anna Rita Molinar Min, Franca Borella, Antonio Borrelli, and Paola Gianella\*.

Department of Veterinary Sciences, University of Turin, Largo P. Braccini, 2-5, 10095, Grugliasco, Italy.

\*Corresponding author at: Department of Veterinary Sciences, University of Turin, Largo P. Braccini, 2-5, 10095, Grugliasco, Italy.  
E-mail: paola.gianella@unito.it

Veterinaria Italiana 2023, 59 (3), x-xx doi: 10.12834/VetIt.2969.19642.2  
Accepted: 18.10.2022 | Available on line: 31.12.2023

## Keywords

Dog,  
Italy,  
Piedmont,  
*S. stercoralis*,  
*Strongyloidiasis*,  
Treatment.

## Summary

*Strongyloides stercoralis* is a zoonotic parasite, infecting human, cats and dogs. The infection is typical of tropical and subtropical areas, while it is underestimated in temperate countries. In Europe, data from humans demonstrate a large variability of infection prevalence; while scarce literature is available for dogs, with most cases reported in kennel dogs from southern Italy. A privately-owned 8-month-old French Bulldog was examined because of chronic cough, diarrhea, and poor body conditions. Radiography of the thorax revealed a diffuse bronchial pattern and abdominal ultrasound showed unspecific signs of inflammation. Cytological analysis of a rectal swab revealed the presence of larvae compatible with *Strongyloides* sp. A parasitic infection causing protein-losing enteropathy and bronchopneumonia was suspected and fenbendazole was administered with a poor clinical response. Fecal Baermann test revealed *S. stercoralis* rhabditiform larvae and thin-shelled eggs. Clinical signs resolved progressively after two subcutaneous ivermectin administrations (off-label) given two weeks apart. Serial coprological controls scheduled in the following 6 months were negative for larvae and eggs. Fecal real-time PCR confirmed negative results 6 months after treatment. The authors describe for the first time a case of *S. stercoralis* infection in a privately-owned dog from north-west of Italy (Piedmont).

## Introduction

*Strongyloides stercoralis* is a world-wide spread intestinal nematode that usually infects both primate and canids, less frequently cats.<sup>1,2,3</sup> It is typically found in tropical and subtropical areas, especially in kennels and intensive breeding facilities.<sup>2,3</sup> This parasite is characterized by a complex life cycle, including a free-living and a host-mediated cycle. Most infections commonly occur through the penetration of third-stage larvae (L3) through the skin or mucous membranes, migrating to the lungs via the hematogenous path, and finally reaching the intestine after swallowing.<sup>4</sup> Both oral and lactogenic transmission are possible in puppies,<sup>3,5</sup> and autoinfection by first-stage larvae (L1), which subsequently develop through to infective L3 within the host, is reported.<sup>4</sup>

In human medicine, recent studies indicate that the infection is not an extinguished problem, and a prevalence up to 8% in some regions of the North of Italy has been reported.<sup>1</sup> In veterinary medicine, the reports of canine strongyloidiasis have increased in the last years, with several cases reported in Southern Italy. So far, no cases have been reported in Piedmont region.<sup>1-3,5-8</sup> Although *S. stercoralis* is considered a zoonosis, recent studies revealed the existence of dog-specific genotype,<sup>9,10</sup> and so it is assumed that zoonotic transmission might occur less frequently.<sup>11,12</sup>

The infection is generally asymptomatic in adult healthy dogs. Clinical manifestations are typical for puppies and immunosuppressed dogs.<sup>2,3,5</sup> Nonspecific gastrointestinal, respiratory or dermatological symptoms may be present, with eosinophilia being less frequently detected than

in humans.<sup>13</sup> In immunocompromised humans and dogs, complicated and potentially fatal clinical syndromes called hyperinfection and disseminated infection may develop.<sup>7,13,14</sup>

Baermann technique and agar plate culture of feces for detection of larvae are traditional techniques with the highest sensitivity.<sup>15,16</sup> Larvae observation on direct smear of fresh feces is also possible.<sup>17,18</sup> However, serological assays have been implemented to further increase the sensitivity.<sup>17,18</sup> In-house IFAT and real-time PCR techniques routinely used for the diagnosis in humans could also be useful for the diagnosis of the infection in dogs.<sup>16</sup>

The aim of this case report was to describe for the first time a case of strongyloidiasis in a privately-owned dog from north-west of Italy (Piedmont). Data recorded would clarify the spectrum of the clinical consequences, the importance of diagnostic methods and the need to regularly include this infection in the differential diagnosis list.

## Case presentation

A 8-month-old, 7 kg, female intact French Bulldog living indoor with regularly taking anthelmintics, was presented for a second opinion to the internal medicine service of a Veterinary Hospital of the Piedmont region for evaluation of chronic hemorrhagic and mucous diarrhea (fecal score of 7; 7-point scale, Purina Fecal Scoring Chart<sup>®</sup>),<sup>19</sup> nasal discharge, cough, and emaciation. The dog was adopted from a local breeding-kennel at the age of 5 months. During the previous months before diagnosis, the dog received different hydrolyzed- and novel-protein diets and different empiric antibiotic trials with doxycycline, amoxicillin/clavulanic acid, and metronidazole (unknown therapeutic regimens), in order to control both gastrointestinal and respiratory signs.

No improvement was achieved. In addition, a fecal examination by flotation test was performed and revealed coccidial parasites. Sulpametopyrazine (Vetkelfizina<sup>®</sup>, Ceva Vetem SpA, Italy) at unknown therapeutic regimen was given without improvement of hemorrhagic and mucous diarrhea, in addition to topical moxidectin/imidacloprid (Advocate<sup>®</sup> spot on, Bayer SpA, Italy) at unknown therapeutic regimen because of alopecia with desquamation and pustules, clinically suspected as demodicosis by a veterinarian.


At clinical examination, mild depression, several fits of cough and reverse sneezing episodes were noticed. A Body Condition Score (BCS) of 3 was assigned to the dog (9-point scale, Nestlé Purina<sup>®</sup>).<sup>20</sup> A digital rectal exam revealed fresh blood and small amount of liquid fecal material. No other abnormalities were detected. Thoracic radiographs showed a mild to

moderate diffuse bronchial pattern. Lesions found on abdominal ultrasound included reactive changes of lymph nodes, small amount of free fluid, scattered hyperechoic small intestinal mucosal striations, thickening of the muscularis layer and abundant liquid content on the colon. Complete blood count revealed eosinophilia (2,670 cells/ $\mu$ l, reference range, RR: 0-1,200 cells/ $\mu$ l). Serum biochemical analysis revealed mild hypoalbuminemia (2.71 g/dl, RR: 2.8-4 g/dl), and mild hypoproteinemia (5.48 g/dL, RR: 5.5-7.2 g/dl). A mild increase of serum C-reactive protein (CRP) concentration (12.3 mg/l, RR: 0-10.7 mg/l) was also observed. Urinalysis and trypsin-like immunoreactivity test were normal. Cytological analysis of a rectal swab revealed the presence of many larvae compatible with *Strongyloides* sp. first-stage larvae (L1), columnar epithelial cells, occasional degenerated neutrophils, rare eosinophils, rare mast cells and numerous bacteria.

A parasitic infection causing protein-losing enteropathy and bronchopneumonia was suspected. The dog was then treated with a high digestible diet, an association of prebiotics and probiotics (Formalife<sup>®</sup>, Bayer, Italy,) 1 tablet, orally, once a day, for 15 days and fenbendazole (Panacur, MSD Animal Health Srl, Italy) 50 mg/kg, orally, once a day, for 15 days. Before starting anthelmintic therapy, the owner was asked to collect multiple fecal specimens on 3 consecutive days. Ten abundant fecal specimens were examined using two different techniques (sedimentation-zinc sulfate flotation and Baermann techniques). The analysis by the sedimentation-flotation method was negative. The Baermann technique, however, revealed a low number of rhabditoid larvae, which were morphologically identified as L1 of *S. stercoralis* (Fig. 1, a-b) and thin-shelled eggs (Fig. 1, c). A new coprological control 20 days after beginning fenbendazole therapy was performed on multiple fecal samples by the Baermann technique and was negative; however, diarrhea and cough were still present. Given the poor clinical response to the anthelmintic therapy and the persistence of clinical signs suggestive of strongyloidiasis, ivermectin (Ivomec<sup>®</sup>, Boehringer Ingelheim Animal Health SpA, Italy) 0.2 mg/kg, subcutaneously, repeated after two weeks, was administered (off-label) along with prednisolone (Prednicortone<sup>®</sup>, Dechra Veterinary Products Srl, Italy) 0.5 mg/kg, orally, once a day, for 10 days. At control 2 weeks after the second ivermectin administration, the dog was active and playful. A complete resolution of the cough and diarrhea with a final fecal score of 2 (7-point-scale, Purina Fecal Scoring Chart<sup>®</sup>),<sup>19</sup> and weight gain of 1 kg were reported by the owner. Physical and digital rectal examinations were normal and a BCS of 4 was assigned (9-point scale, Nestlé Purina<sup>®</sup>)<sup>20</sup> to the dog. Neither *S. stercoralis* larvae nor eggs were observed

during fecal examinations (cytological analysis and Baermann technique). Eosinophilia disappeared, serum albumin (3.3 g/dl, RR: 2.8-4 g/dl), serum total protein (5.9 g/dL, RR: 5.5-7.2 g/dl) and serum CRP (2.3 mg/l, RR: 0-10.7 mg/l) concentrations turned normal. During the following months, several fresh fecal samples were analysed by cytology and the Baermann technique, and all resulted negative for the presence of *S. stercoralis*. Six months after the second ivermectin administration, physical

examination was normal, a body weight of 10.5 kg was recorded and a BCS of 6 was assigned to the dog. Neither gastrointestinal nor respiratory signs were reported by the owner. In addition to the coprological analyses (smear of fresh feces and Baermann technique), a fecal sample was shipped to the Centre for Tropical Disease of Negrar hospital, Verona (Italy) for execution of real-time PCR. Coprological analyses were negative for *S. stercoralis*, as well as real-time PCR.



**Figure 1.** Microscopic appearance of *Strongyloides stercoralis*: a) chains of thin-shelled eggs (85.8 [75.0–95.0] × 37.5 [35.0–40.0], scale bar 50 µm); b) rhabditiform pharynx, characterized by double bulb oesophage (red arrow), scale bar 10 µm; c) first-stage (L1) larvae of *S. stercoralis* [325 µm (300–340); scale bar 50 µm. 16.4 µm (12.5–17.5)] with the esophagus 88,7 µm (82.5–92.5) long, scale bar 30 µm;

## Discussion

Herein, the Authors describe the first report of *S. stercoralis* in a privately-owned dog from north-west of Italy (Piedmont) including pertinent details about its history, clinical, hematological, and parasitological findings, as well as specific anti-parasitic treatments and long-term follow-up.

In the last decade an increasing number of *S. stercoralis* infections have been reported in different European countries, as far west as the UK and as far north as Iceland and Scandinavia.<sup>8,21–23</sup> Although infection is more common in warm climate area, the parasite can survive and successfully complete its life cycle at lower environmental temperatures;<sup>23</sup> therefore, it is not surprising an infection in the Piedmont, one of the coldest regions of Italy.

*S. stercoralis* infections are often asymptomatic, and disease occurs mainly in massively challenged neonates and nurslings.<sup>21,24</sup> In dogs, severe infections cause bronchopneumonia and watery to mucous diarrhea,<sup>21</sup> and the condition can be easily confused with other generalized viral diseases common in puppies.<sup>24</sup> In this case, although the clinical features and the laboratory changes were unspecific, a generalized parasitic infection of the gut and lung was supported by the presence of gastrointestinal and respiratory impairment of some months duration, peripheral eosinophilia, panhypoproteinemia, and increase in CRP. Peripheral eosinophilia, although reported in both human and canine strongyloidiasis, is not a constant finding.<sup>5,25</sup> Eosinophils may play an important role in defense mechanisms against *S. stercoralis* larvae;<sup>26</sup> however, a defense collapse

with low to normal number of eosinophils may explain the possibility of severe parasitosis in the absence of eosinophilia.<sup>26</sup> The inadequate weight gain and panhypoproteinemia of the dog during the infection, the weight gain and the resolution of the panhypoproteinemia after the ivermectin administration suggest the effects of *S. stercoralis* on the ability of the dog to absorb nutrients for essential metabolism and growth. Measurement of the levels of acute-phase proteins is of clinical importance in determining the presence and extent of inflammatory tissue damage as well as in providing diagnostic and prognostic information in infectious diseases and oncological disorders.<sup>27,28</sup> In human medicine, *S. stercoralis* infection is associated with elevated levels of acute-phase proteins and markers of inflammation.<sup>29</sup> In this case, serum concentration of CRP was increased before treatment, suggesting a systemic inflammatory reaction. After ivermectin administration, serum concentration of CRP normalized, indicating that *S. stercoralis* infection was directly associated with an enhanced acute-phase response.<sup>29</sup>

In human medicine, the infection may also manifest with urticaria or larva currens.<sup>14,21</sup> To the authors' knowledge, cutaneous manifestations of *S. stercoralis* are seldom reported in dogs,<sup>30</sup> although it has been recently demonstrated that the infective larva of *S. stercoralis* is strongly attracted by a component of the dog's skin.<sup>31</sup> At the time of clinical examination no cutaneous signs were observed in this dog. However, alopecia with desquamation and pustules were noticed before diagnosis. A suspicion of demodicosis was raised by a veterinarian and a topical administration of moxidectin/imidacloprid (Advocate® spot on, Bayer SpA, Italy) was given with a complete resolution of the lesions. Since the demodicosis was never confirmed by a deep skin scraping, a dermatitis caused by *S. stercoralis* larvae cannot be excluded. Indeed, the topical therapy with moxidectin/imidacloprid is reported among the treatment protocols for *S. stercoralis*.<sup>5</sup>

Results from this case confirm that routine copromicroscopic methods may fail to diagnose *S. stercoralis* infection, as previously reported.<sup>2,32</sup> Indeed, even when present, larvae in feces become easily altered when saturated salt solutions are added.<sup>21</sup> Therefore, fresh fecal smears and the Baermann technique are required, although the sensitivity of these methods may be low because worms may be shed in low numbers and intermittently.<sup>33</sup> In this case, in addition to a fresh fecal smear, both the sedimentation-flotation and the Baermann techniques were performed on multiple and abundant fecal specimens collected on 3 consecutive days. Only the analyses by fresh fecal smear and Baermann technique turned positive for *S. stercoralis*. Two recent studies suggest that

molecular (RT-PCR) techniques routinely used for *S. stercoralis* diagnosis in humans could be useful for the diagnosis of the infection in dogs.<sup>16,34</sup>

However, only 4 fecal samples were tested in the former,<sup>16</sup> while a variable and inconstant positivity to pre-treatment fecal real-time PCR was observed in the latter.<sup>34</sup> Therefore, to date, the Baermann test remains the most frequently used test *in vivo* for the diagnosis.<sup>16-18</sup>

In humans, ivermectin is currently the most effective therapy at a dose of 200 µg/kg with cure rates up to 97% using a two-days course in asymptomatic cases.<sup>29,31</sup> In the veterinary counterpart, a standardized therapeutic protocol has not been defined yet and information on treatments is based on single cases or small case series.<sup>2,6,26,32-35</sup> Fenbendazole has been proposed alone or in combination with imidacloprid/moxidectin spot-on in naturally infected symptomatic dogs.<sup>4</sup> However, the treatment did not consistently result in the elimination of the infection.

Some efficacious results have been achieved with off-label dosage of ivermectin given orally at different dosage schedules or subcutaneously in single or repeated injections.<sup>2,6,10,21,35</sup> The dog of this report received topical moxidectin/imidacloprid for a clinical suspicion of demodicosis some months before diagnosis. This treatment led to resolution of only dermatologic signs. Afterwards, fenbendazole was given for 15 days without significant clinical improvement. Therefore, ivermectin off-label was given subcutaneously two weeks apart with a progressive and complete resolution of clinical signs and the cease of larvae and eggs shedding, as confirmed by persistent fecal negative results (both at cytology and Baermann tests) throughout the post-treatment follow-up. Although imidacloprid/moxidectin and fenbendazole may have contributed to reduce the parasitic load and severity of symptoms, it seems that only the additional administration of ivermectin was highly effective in this dog.

Fecal real-time PCR was used at 6-month follow-up in this dog.

Indeed, the addition of fecal monitoring by molecular tools might be a better choice when evaluating the efficacy of treatment in individual dogs.<sup>35</sup>

## Conclusion

In conclusion, the Authors describe for the first time a case of *S. stercoralis* infection in a privately-owned dog from north-west of Italy (Piedmont).

From an epidemiological point of view, the present report demonstrates the presence of this parasite in a

new region compared to those previously reported. Indeed, the dog lived in a regional breeding-kennel where he may have contracted the infestation. Since this infection is probably underestimated, especially in cold climate area, small animal clinicians should be aware of this disease among young dogs during the evaluation of differentials for gastrointestinal and/or respiratory signs. Moreover, since routine

fecal flotation methods have low sensitivity for detection of L1, in case of gastrointestinal and/or respiratory signs, the authors suggest both direct fecal smear analysis and Baermann techniques on multiple and abundant fecal specimens for a correct diagnosis and monitoring, in addition to real-time PCR to evaluate the efficacy of treatment.

## References

- Buonfrate D, Baldissera M, Abrescia F, et al. Epidemiology of *Strongyloides stercoralis* in Northern Italy: results of a multicentre case-control study. *Euro Surveill* **21**: 30310, 2016. <http://doi.org/10.2807/1560-7917.ES.2016.21.31.30310>
- Basso W, Grandt LM, Magnenat AL, et al. *Strongyloides stercoralis* infection in imported and local dogs in Switzerland: from clinics to molecular genetics. *Parasitol Res* **118**: 255-66, 2019. <http://doi.org/10.1007/s00436-018-6173-3>
- Schnyder M, Reichler IM, Eichenberger RM, et al. *Strongyloides stercoralis* in swiss dogs - a retrospective study suggests an increasing occurrence of this potentially zoonotic parasite as a consequence of dog imports. *Schweiz Arch Tierheilkd* **164**: 89-104, 2022. <http://doi.org/10.17236/sat00340>
- Viney M. *Strongyloides*. *Parasitol* **19**:1-4, 2016. <http://doi.org/10.1017/S0031182016001773>
- Dillard KJ, Seppo AMS, Marjukka A. *Strongyloides stercoralis* infection in a finnish kennel. *Acta Vet Scand* **49**: 37, 2007. <http://doi.org/10.1186/1751-0147-49-37>
- Paradies P, Iarussi F, Sasanelli M, et al. Occurrence of strongyloidiasis in privately owned and sheltered dogs: clinical presentation and treatment outcome. *Parasit Vectors* **10**:345, 2017. <http://doi.org/10.1186/s13071-017-2275-5>
- Jourdan PM, Lambert PHL, Fenwick A, et al. Soil-transmitted helminth infections. *Lancet* **391**: 252-265, 2018. [http://doi.org/10.1016/S0140-6736\(17\)31930-X](http://doi.org/10.1016/S0140-6736(17)31930-X)
- Thamsborg SM, Ketzis J, Horii Y, et al. *Strongyloides* spp. infections of veterinary importance. *Parasitol* **144**:274-84, 2017. <http://doi.org/10.1017/S0031182016001116>
- Concha R, Harrington Jr W, Rogers AI. Intestinal strongyloidiasis: recognition, management and determinants of outcome. *J Clin Gastroenterol* **39**:203-211, 2005. <http://doi.org/10.1097/O1.mcg.0000152779.68900.33>
- Cervone M, Giannelli A, Otranto D, et al. *Strongyloides stercoralis* hyperinfection in an immunosuppressed dog from France. *Rev Vet Clin* **51**: 55-59, 2016. <http://doi.org/10.1016/j.anicom.2016.005.01>
- Nutman TB Human infection with *Strongyloides stercoralis* and other related *Strongyloides* species. *Parasitol* **144**: 263-73, 2017. <http://doi.org/10.1017/S0031182016000834>
- Keiser PB, Nutman TB. *Strongyloides stercoralis* in the immunocompromised population. *Clin Microbiol Rev.* **17**: 208-217, 2004. <http://doi.org/10.1128/CMR.17.1.208-217.2004>
- Gonçalves ALR, Machado GA, Gonçalves-Pires MRF, et al. Evaluation of strongyloidiasis in kennel dogs and keepers by parasitological and serological assays. *Vet Parasitol* **147**: 132-139, 2007. <http://doi.org/10.1016/j.vetpar.2007.03.016>
- Nolan TJ. Canine Strongyloidiasis. In: Companion and Exotic Animal Parasitology, Ed. Bowman DD., 2001. Accessed October 4, 2022. [http://www.ivis.org/advances/Parasit\\_Bowman/nolan\\_strongyloidiasis/chapter\\_frm.asp?LA=1](http://www.ivis.org/advances/Parasit_Bowman/nolan_strongyloidiasis/chapter_frm.asp?LA=1)
- Júnior Ferreira A, Gonçalves-Pires M.R.F, Silva D.A.O, Gonçalves A.L.R, Costa-Cruz J.M. Parasitological and serological diagnosis of *Strongyloides stercoralis* in domesticated dogs from southeastern Brazil. *Vet Parasitol* **136**:137-145, 2006. <http://doi.org/10.1016/j.vetpar.2005.10.022>
- Buonfrate D, Paradies P, Iarussi F, et al. Serological and molecular tests for the diagnosis of *Strongyloides stercoralis* infection in dogs. *Parasitol Res* **116**: 2027-2029, 2017. <http://doi.org/10.1007/s00436-017-5468-0>
- Zanzani SA, Gazzonis AL, Scarpa P, et al. Intestinal parasites of owned dogs and cats from metropolitan and micropolitan areas: prevalence, zoonotic risks, and pet owner awareness in northern Italy. *Biomed Res Int* **14**: 1-10, 2014. <http://doi.org/10.1155/2014/696508>
- Ottino L, Buonfrate D, Paradies P, et al. Autochthonous human and canine *Strongyloides stercoralis* infection in Europe: report of a human case in an italian teen and systematic review of the literature. *Pathogens* **9**: 439, 2020. <http://doi.org/10.3390/pathogens9060439>
- Asano K, Suzuki K, Matsumoto T, et al. Prevalence of dogs with intestinal parasites in Tochigi, Japan in 1979, 1991 and 2002. *Vet. Parasitol* **120**:243-248, 2004. <http://doi.org/10.1016/j.vetpar.2004.01.009>
- Jaleta TG, Zhou S, Bemm FM, et al. Different but overlapping populations of *Strongyloides stercoralis* in dogs and humans-dogs as a possible source for zoonotic Strongyloidiasis. *PLoS Negl Trop Dis* **11**: e0005752, 2017. <http://doi.org/10.1371/journal.pntd.005752>
- Nagayasu E, Aung M, Hortiwakul T, et al. A possible origin population of pathogenic intestinal nematodes, *Strongyloides stercoralis*, unveiled by molecular phylogeny. *Sci Rep* **7**: 4844, 2017. <http://doi.org/10.1038/s41598-017-05049-x>
- Takano Y, Minakami K, Kodama S, et al. Cross infection of *Strongyloides* between humans and dogs in the

- Amami Islands, Japan. *Trop Med Health* **37**: 149-52, 2009. <http://doi.org/10.2149/TMH.2009-16>
- Purina Fecal Score Chart [Online]. <https://www.purinainstitute.com/sites/g/files/auxxlc381/files/2021-04/fecal-chart.pdf>. Accessed May, 2022
- Purina Body Condition System Chart [Online]. [https://www.purina.com/sites/g/files/auxxlc196/files/2021-01/BodyCondition\\_Dog\\_122120.pdf](https://www.purina.com/sites/g/files/auxxlc196/files/2021-01/BodyCondition_Dog_122120.pdf). Accessed May, 2022
- Robertson ID, Thompson RC. Enteric parasitic zoonoses of domesticated dogs and cats. *Microbes Infect* **4**: 867-873, 2002. [http://doi.org/10.1016/S1286-4579\(02\)01607-6](http://doi.org/10.1016/S1286-4579(02)01607-6)
- Abrescia FF, Falda A, Caramaschi G, et al. Reemergence of Strongyloidiasis, Northern Italy. *Emerg Infect Dis* **15**: 1531-1533, 2009. <http://doi.org/10.3201/eid1509.090191>
- Iriemenam NC, Sanyaolu AO, Oyibo WA, et al. Strongyloides stercoralis and the immune response. *Parasitol Int* **59**: 9-14, 2010. <http://doi.org/10.1016/j.parint.2009.10.009>
- Johnson HL, Chiou CC, Cho CT. Applications of acute phase reactants in infectious diseases. *J Microbiol Immunol Infect* **32**: 73-82, 1999
- Peracaula R, Sarrats A, Rudd PM. Liver proteins as sensor of human malignancies and inflammation. *Proteomics Clin Appl* **4**: 426-431, 2010. <http://doi.org/10.1002/prca.200900170>
- Rajamanickam A, Munisankar S, Bhootra Y, et al. Microbial translocation associated with an acute-phase response and elevations in MMP-1, HO-1, and proinflammatory cytokines in *Strongyloides stercoralis* infection. *Infect Immun* **85**: e00772-16, 2017. <http://doi.org/10.1128/IAI.00772-16>
- Hendrix CM, Blagburn BL, Lindsay DS. Whipworms and intestinal threadworms. *Vet Clin N Am Small Anim Pract* **17**: 1355-1375, 1982. [http://doi.org/10.1016/S0195-5616\(87\)50006-7](http://doi.org/10.1016/S0195-5616(87)50006-7)
- Safer D, Brenes M, Dunipace S, et al. Urocanic acid is a major chemoattractant for the skin-penetrating parasitic nematode *Strongyloides stercoralis*. *Proc Natl Acad Sci* **104**: 1627-1630, 2007. <http://doi.org/10.1073/pnas.0610193104>
- Lee E, Seo K, Song K. Treatment of *Strongyloides stercoralis* hyperinfection in a dog. *J Vet Clin* **38**: 210-212, 2021. <https://doi.org/10.17555/jvc.2021.38.4.210>
- Siddiqui AA, Berk SL. Diagnosis of *Strongyloides stercoralis* infection. *Clin Infect Dis* **33**: 1040-1047, 2001. <http://doi.org/10.1086/322707>
- Paradies P, Buonfrate D, Iatta R, et al. Efficacy of ivermectin to control *Strongyloides stercoralis* infection in sheltered dogs. *Acta Trop* **190**: 204-209, 2019. <http://doi.org/10.1016/j.actatropica.2018.11.014>
- Mansfield LS, Schad GA. Ivermectin treatment of naturally acquired and experimentally induced *Strongyloides stercoralis* infections in dogs. *JAVMA* **201**:726-730, 1992.